SEC Form 4 · accession 0001114220-18-000056
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott A Holmes
Officer — Chief Financial Officer
Period of report
May 15, 2018
Accepted (ET)
May 16, 2018 · 4:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 15, 2018 | S | 1,158 | $5.69 | D | 168,904 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale of a total of 1,158 shares of common stock was made in order to satisfy Mr. Holmes' income tax withholding obligation upon the vesting of 4,063 shares of restricted stock on May 14, 2018. Mr. Holmes had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.
- F2Includes 86,872 shares of restricted stock.